Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959786 | 0.96 | TRPA1 (0.41) | DRD2TRPA1NAPRTPDE10AHRH3 | |
| SCHEMBL19284042 | 0.94 | TRPA1 (0.40) | DRD2TRPA1NAPRTPDE10AHRH3 | |
| SCHEMBL3602093 | 0.92 | DRD2 (0.41) | DRD2TRPA1NAPRTPDE10AADRA2A | |
| SCHEMBL29695056 | 0.92 | DRD2 (0.41) | DRD2TRPA1NAPRTPDE10AADRA2A | |
| SCHEMBL19284003 | 0.84 | OGA (0.40) | DRD2TRPA1NAPRTPDE10AHRH3 | |
| SCHEMBL1750265 | 0.84 | DRD2 (0.61) | DRD2TRPA1NAPRTPDE10A | |
| SCHEMBL12558093 | 0.81 | CDK4 (0.38) | DRD2TRPA1NAPRTPDE10AIDO1 | |
| SCHEMBL19283986 | 0.79 | WDR91 (0.40) | TRPA1NAPRTPDE10AADRA2AADRA2B | |
| SCHEMBL31572560 | 0.79 | WDR91 (0.40) | TRPA1NAPRTPDE10AADRA2AADRA2B | |
| SCHEMBL19283972 | 0.78 | OGA (0.42) | TRPA1NAPRTPDE10AHRH3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626892-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024118460-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-11091460-B2 | Syk inhibitor and use method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-110678461-B | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| CN-110678461-A | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091460-B2 | Syk inhibitor and use method therefor | SYK, BTK, LCK | DRD2 4064/4885TRPA1 3096/4885NAPRT 1411/4885 |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | SYK, BTK, LCK | DRD2 4064/4885TRPA1 3096/4885NAPRT 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.